secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0001193125-23-105679
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Agios director Paul Clancy to retire; Jeff Capello elected to board, to chair Audit Committee
--------------------------------------------------------------------------------

- Paul Clancy will not stand for re-election at 2023 Annual Meeting; ceases as Audit Committee chair and Compensation & People Committee member.
- Jeff Capello elected as class II director effective at 2023 Annual Meeting; appointed Audit Committee chair.
- Capello receives $50,000/yr director cash retainer plus $20,000/yr for Audit Chair role; initial equity grant of stock options ($472,500 Black-Scholes) and RSUs ($157,500).
- Capello enters into standard indemnification agreement with the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/0001193125-23-105679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/d499411d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-105679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer